GB-7624 / Generate Biomedicines - LARVOL DELTA

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Generate Biomedicines | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Dec 2026

Enrollment closed • First-in-human • Trial completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Phase 1, First in Human, Randomised, Double-Blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Investigate the Safety, Tolerability and Pharmacokinetics of GB-7624 administered subcutaneously in Healthy Adult participants (ANZCTR) - P1 | N=40 | Active, not recruiting | Sponsor: Generate Biomedicines Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Generate Biomedicines

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology